The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis

Expert Review of Clinical Immunology

Volumn 7, Issue 6, 2011, Pages 803-815

  Mockenhaupt, Maja ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

incidence; mortality; SCAR; sequelae; severe cutaneous adverse reactions; SJS; Stevens'Johnson syndrome; TEN; toxic epidermal necrolysis; treatment

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUPROFEN; INSULIN; LAMOTRIGINE; MACROLIDE; MELOXICAM; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; OXICAM DERIVATIVE; PHENOBARBITAL; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALPROIC ACID;

DISEASE SEVERITY; ERYTHEMA MULTIFORME; EYE DISEASE; GENETIC SUSCEPTIBILITY; HUMAN; MORTALITY; PATHOGENESIS; PROGNOSIS; REVIEW; RISK FACTOR; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EPIDERMAL NECROLYSIS, TOXIC; EYE DISEASES; HUMANS; INFECTION; MUCOUS MEMBRANE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME;

EID: 80054939885     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.66     Document Type: Review

References (42)

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92-96 (1993)
2. Salopek TG. Nikolsky's sign: is it 'dry' or is it 'wet'? Br. J. Dermatol. 136, 762-767 (1997)
3. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch. Dermatol. 138, 1019-1024 (2002)
4. Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exsudativum multiforme majus (EEMM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Br. J. Dermatol. 135, 6-11 (1996)
5. Ziemer M, Wiesend CL, Vetter R, et al. Cutaneous adverse drug reactions to valdecoxib distinct from Stevens- Johnson syndrome and toxic epidermal necrolysis. Arch. Dermatol. 143, 711-716 (2007)
6. Liss Y, Mockenhaupt M for the RegiSCAR-study group. Erythema exsudativum multiforme majus versus Stevens-Johnson syndrome: differences in clinical pattern and etiology. Presented at: Meeting on Cutaneous Adverse Drug Reactions and ESDR, Paris, France, 7-9 September 2006. J. Invest. Dermatol. 126, 106 (2006)
7. Mockenhaupt M, Idzko M, Grosber M, Schöpf E, Norgauer J. Epidemilogy of staphylococcal scalded skin syndrome in Germany. J. Invest. Dermatol. 124, 700-703 (2005)
8. Mockenhaupt M. [Severe drug induced skin reactions: clinical pattern, diagnostic and therapy]. J. Dtsch. Dermatol. Ges. 7 (2), 142-163 (2009)
9. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br. J. Dermatol. 157, 989-996 (2007)
10. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus (EEMM), Stevens- Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Germany (1990-1992). Structure and results of a population-based registry. J. Clin. Epidemiol. 49, 769-773 (1996)
11. Mockenhaupt M. Severe cutaneous adverse reactions. In: Braun-Falco's Dermatology (3rd Edition). Burgdorf WHC, Plewig G, Wolff HH, Landthaler M (Eds). Springer Medizin Verlag, Heidelberg, Germany, 473-483 (2008)
12. Fagot JP, Mockenhaupt M, Bouwes Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis - preliminary results of a case-control study. AIDS 15, 1-6 (2001)
13. Grosber M, Carsin H, Leclerc F. Epidermal necrolysis in association with Mycoplasma pneumoniae infection. Presented at: Meeting on Cutaneous Adverse Drug Reactions and ESDR, Paris, France, 7-9 September 2006. J. Invest. Dermatol. 126, 23 (2006)
14. Sassolas B, Haddad C, Mockenhaupt M, et al.; the Regi-SCAR-group. ALDEN an algorithm for assessment of drug causality in Stevens-Johnson-syndrome and toxic epidermal necrolysis. Comparison with case-control analysis. Clin. Pharmacol. Ther. 88(1), 60-68 (2010)
15. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of anti-epileptics. Neurology 64, 1134-1138 (2005)
16. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333, 1600-1607 (1995)
17. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128 (1), 35-44 (2008)
18. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58 (1), 25-32 (2008)
19. Nassif A, Moslehi H, Le Gouvello S, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114(5), 1209-1215 (2004)
20. Chung WH, Hung SI, Yang JY,, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14(12), 1343-1350 (2008)
21. Morel E, Escamochero S, Caba'as R, D'az R, Fiandor A, Bell'n T. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J. Allergy Clin. Immunol. 125(3), 703-710, 710.e1-710.e8 (2010)
22. Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J. Allergy Clin. Immunol. 127(3 Suppl.), S74-S81 (2011)
23. Chung WH, Hung SI, Hong HS et al A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004)
24. Lonjou C, Thomas L, Borot N,, et al. A marker for Stevens-Johnson- syndrome and toxic epidermal necrolysis: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006)
25. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005)
26. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18 (2), 99-107 (2008)
27. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA . Drug hypersensitivity: pharmacogenetics and clinical syndromes. J. Allergy Clin. Immunol. 127(3 Suppl.), S60-S66 (2011)
28. Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med. 36(1), 22-32 (2010)
29. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 62, 527-531 (2007)
30. Gregory DG. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocul. Surf. 6, 87-95 (2008)
31. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol. Online J. 1, 5 (2002)
32. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens- Johnson syndrome/toxic epidermal necrolysis. Acta Derm. Venereol. 87(2), 144-148 (2007)
33. Araki Y, Sotozono C, Inatomi T. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am. J. Ophthalmol. 147(6), 1004-1011, 1011.e1 (2009)
34. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg). Clinical experience to date. Drugs 65(15), 2085-2090 (2005)
35. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch. Dermatol. 139, 33-36 (2003)
36. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Invest. Dermatol. 115, 149-153 (2000)
37. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J. Invest. Dermatol. 126(2), 272-276 (2006)
38. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL Toxic epidermal necrolysis: does immunoglobulin make a difference? J. Burn Care Rehabil. 25, 81-88 (2004)
39. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J. Burn Care Rehabil. 25, 246-255 (2004)
40. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens- Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J. Am. Acad. Dermatol. 58 (1), 33-40 (2008)
41. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br. J. Dermatol. 163(4), 847-853 (2010)
42. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch. Dermatol. 136, 323-327 (2000)